Lecture Details - Overview

View all Online CME

Continuing Education Information

Physicians' Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Expert Interviews in Lung Cancer: Optimizing Current Approaches to the Treatment of NSCLC

Release Date: March 5, 2009| Expiration Date: March 5, 2010
Mar 5, 2009, Expert Interviews

Lecture Overview

For decades, little progress was observed in the treatment of advanced non–small-cell lung cancer (NSCLC). More recently, the development of improved chemotherapeutic agents and targeted agents has provided effective treatment choices. Additionally, new approaches to administering chemotherapy, including maintenance following completion of a frontline doublet, have the potential to prolong responses and survival in patients with advanced NSCLC.

The purpose of this activity is to inform physicians of novel cytotoxic and targeted approaches to the treatment of lung cancer.

This educational activity is intended for medical oncologists involved in the care of patients with lung cancer. No specific skills or knowledge other than a basic training in oncology is required for successful participation in this activity.

Upon completion of this educational activity, you should be able to:

  • Discuss the efficacy and safety of maintenance chemotherapy following a frontline doublet in metastatic NSCLC
  • Assess the efficacy and adverse event profile of frontline epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced NSCLC
  • Describe clinical data on antiangiogenic agents used with various chemotherapy backbones in metastatic NSCLC

Instructions for Participation

  1. Read the following information before entering the educational activity.
  2. Complete the Pretest.
  3. View and study Flash video presentation and slides.
  4. Complete the Posttest.
  5. Answer the evaluation questions.
  6. After completion of the Pretest and successful completion of the Posttest and evaluation, you will receive your certificate online.
  • You will be permitted 2 attempts to successfully complete the Posttest.

Read all of the conditions in the Activity Terms box below. You must accept the Activity Terms in order to continue:

Disclosure Policy

It is the policy of Physicians’ Education Resource to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Physicians’ Education Resource requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. Physicians’ Education Resource has implemented a mechanism to identify and resolve all conflicts of interest prior to the activity.

Joan Hoff Schiller, MD
Research Funding – AstraZeneca; Genentech, Inc.; Geron; Novartis Pharmaceuticals Corporation; Pfizer Inc.
Paid Consultant – AstraZeneca; Bayer Pharmaceuticals Corporation; Bristol-Myers Squibb Company; Eli Lilly and Company; Genentech, Inc.; Geron; Novartis Pharmaceuticals Corporation; Pfizer Inc.

H. Jack West, MD
Paid Consultant – Eli Lilly and Company, ImClone Systems Incorporated
Speaker’s Bureau – Eli Lilly and Company

Nasser H. Hanna, MD
Research Funding – AstraZeneca; Bristol-Myers Squibb Company; Eli Lilly and Company; Genentech, Inc.
Paid Consultant – Celgene Corporation; Merck & Co., Inc.
Speaker’s Bureau – Eli Lilly and Company; Genentech, Inc.

PER Editorial Staff
No relevant relationships to disclose

This activity includes discussion of investigational and/or unlabeled uses of drugs, including the use of bevacizumab/erlotinib, cetuximab, and pemetrexed/carboplatin/bevacizumab in NSCLC and gefitinib in previously untreated NSCLC.

Commercial Support

An educational grant for this activity was provided by Lilly Oncology.

Software Requirements

The Web pages and Web-based applications require a minimum Web browser of Microsoft Internet Explorer 5.5 or higher, Mozilla Firefox 1.0 or higher, or another compatible Web browser.

If you are not sure of the version of your browser, select Help in the menu bar of your browser, then select About.

PC Users
If you need to upgrade your Web browser, follow one of the links listed below:

Macintosh Users
Compatible Web browsers include:

Disclaimer

The views and opinions expressed in this activity are those of the authors and do not necessarily reflect the views of the sponsor, supporter, or publisher. Although great care has been taken in compiling and checking the information given in this activity to ensure accuracy, the authors and Physicians’ Education Resource and its servants or agents shall not be responsible or in any way liable for the continued currency of the information or for any errors, omissions, or inaccuracies in this activity, whether arising from negligence or otherwise howsoever or for any consequences arising therefrom.

Please consult full prescribing information for any drugs or procedures discussed within.

Privacy Policy

Physicians’ Education Resource (PER) makes reasonable efforts to ensure that privacy issues are handled responsibly. PER does not sell or share your information with other organizations that are not directly involved in this process. If you have further concerns, you may contact us at (888) 949-0045.

All rights reserved. No part of this activity may be translated, reproduced, stored, or transmitted by any means or in any type of media form including electronic, mechanical photocopying, recording, broadcasting, or otherwise without prior permission from the publisher.

©Copyright 2009 by Physicians’ Education Resource. No material may be reproduced in whole or in part, in any form, without written permission from the publisher.

All correspondence should be directed to:
Editor, Expert Interviews in Lung Cancer
Physicians’ Education Resource
3500 Maple Ave.
Suite 700
Dallas, TX 75219
Phone: (214) 367-3400
Fax: (214) 367-3304
E-mail: editor@cancerlearning.com

Educational Grants

An educational grant for this activity was provided by:


  1. Lilly Oncology